Group 1 - The core point of the news is that the controlling shareholder of Yiyigou, Li Yanfei, has signed a share transfer agreement with Gan Meng, transferring 5.23% of the company's total shares for a total price of 120 million RMB, aimed at optimizing the shareholder structure and introducing quality resources for the company's development [1] - The share transfer is not intended to seek control of the company, but rather to enhance the company's competitiveness and support its sustainable development through collaboration in areas such as industrial chain synergy and new business cultivation [1] - Gan Meng, who is a board member of Sichuan Hezhong Yiyigou Pharmaceutical Co., Ltd., will participate in the company's long-term strategic planning and major investment decisions, bringing valuable experience to the company [1] Group 2 - Gan Meng emphasizes the need for medical innovation to focus on patient value, advocating for technology development that addresses clinical needs rather than merely pursuing commercialization [2] - He believes that the core competitiveness of digital healthcare lies in "data-driven precision diagnosis," which requires establishing industry standards through multi-center clinical research [2] - Gan Meng's involvement is expected to drive the company's transformation towards an "pharmaceutical + technology + health" ecosystem [2]